View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 6, 2020

Bangladesh signs Covid-19 vaccine deal with Serum Institute of India

Bangladesh has entered into a deal with the Serum Institute of India (SII) to acquire 30 million doses of a potential vaccine being developed by AstraZeneca for Covid-19.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

SII and Bangladesh’s drugmaker Beximco Pharma signed a Memorandum of Understanding (MoU) for priority delivery of the vaccine doses.

Under the deal, Beximco will purchase five million doses of vaccine per month.

Reuters quoted Bangladesh Health Minister Zahid Maleque as saying in a statement: “Whenever the vaccine is ready, the Serum Institute will give us 30 million doses in the first phase.

“We’ll be able to vaccinate 15 million people as two shots of vaccine are required for each person 28 days apart.”

SII will supply the vaccine at a price of around $4 to $5 per dose, a rate similar to what India pays.

It partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to produce a billion Covid-19 vaccine for supply worldwide.

In September, SII expanded its alliance with Gavi and the Bill & Melinda Gates Foundation to produce and deliver up to an additional 100 million doses for low-and middle-income countries (LMICs).

SII is currently conducting trials for three potential Covid-19 vaccines, which includes a vaccine licensed to AstraZeneca by UK’s Oxford University.

AstraZeneca said that it is holding back the vaccine deliveries to maximise the shelf-life of supplies as it is anticipating data from late-stage trials soon.

The British-Swedish drugmaker has signed supply with many countries including the US, UK, Australia, China, Brazil and the European Union (EU) Member States.

It also signed manufacturing deals with companies and governments around the world.

According to the trial data in October, the vaccine demonstrated to induce an immune response in both old and young adults.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology